AB-CHMINACA

AB-CHMINACA is a synthetic cannabinoid that was first identified in 2014. It is one of several synthetic cannabinoids that have been identified in products marketed as "herbal incense" or "spice". AB-CHMINACA is a potent agonist of the CB1 receptor and CB2 receptor and is fully substituted for Δ9-THC in rat discrimination studies, while being 16x more potent.

History

AB-CHMINACA was first identified in September 2014. It is one of several synthetic cannabinoids to have been identified in products marketed as "herbal incense" or "spice". Synthetic cannabinoids have been produced for over a decade and are commonly used in research. The use of synthetic cannabinoids can be associated with psychosis and physicians are beginning to investigate if some patients with inexplicable psychotic symptoms may have at one point used synthetic cannabinoids.

Pharmacology

AB-CHMINACA is a potent full agonist of the CB1 receptor (Ki = 0.78 nM) and CB2 receptor (Ki = 0.45 nM) and is fully substituted for Δ9-THC in rat discrimination studies, while being 16x more potent. Continuing research might lead to more knowledge about how this substance functions and the extent of its health benefits.

Legal Status

As of October 2015 AB-CHMINACA is a Schedule I controlled substance in the United States.

See Also

• Synthetic cannabinoids
• Cannabinoid receptor
• Δ9-THC

AB-CHMINACA Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski